^
    CANCER:

    T Cell Non-Hodgkin Lymphoma





    Show legend
    Group by Gene:
    Include preclinical:

    belinostat
    		0
    HDAC inhibitor
    romidepsin
    vorinostat
    ceritinib
    		1
    ALK inhibitor
    alectinib
    crizotinib
    2
    DNA synthesis inhibitor
    nelarabine
    gemcitabine
    3
    IL-2 stimulant
    denileukin diftitox
    4
    PD-L1 inhibitor
    sugemalimab
    durvalumab
    5
    Retinoid X receptor modulator
    bexarotene oral
    6
    Topoisomerase II inhibitor
    etoposide IV
    7
    DNA replication inhibitor
    bendamustine
    8
    CD52 inhibitor
    alemtuzumab
    9
    Alkylating agent
    cyclophosphamide
    10
    Proteasome inhibitor
    bortezomib
    11
    THF dehydrogenase inhibitor
    pralatrexate
    pembrolizumab
    		12
    PD1 inhibitor
    nivolumab
    geptanolimab
    13
    CXCL12 inhibitor, Farnesyl transferase inhibitor
    tipifarnib
    14
    JAK1 inhibitor
    DZD4205
    15
    CDK9 inhibitor
    SLS009
    16
    PIK3CA inhibitor, PI3Kδ inhibitor
    copanlisib
    17
    STAT3 protein degrader
    KT-333
    18
    CD70 inhibitor
    ARGX-110
    19
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    gemcitabine + doxorubicin hydrochloride
    20
    CD20 inhibitor
    rituximab
    21
    PARP inhibitor
    fluzoparib
    CHOP
    EPOCH
    DHAX
    DHAP
    ICE
    GemOx
    GDP
    		22
    Chemotherapy
    GVD
    ESHAP
    CHOEP
    BV-ICE
    CHEP-BV
    CMOP
    CVAD
    CEOP-E
    DICE
    23
    CD30-targeted antibody-drug conjugate, Microtubule inhibitor
    brentuximab vedotin
    TEQ102
    24
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    25
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
    lenalidomide
    26
    ALK inhibitor, EGFR inhibitor
    brigatinib
    27
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    28
    Tubulin polymerization promoter, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
    carboplatin + cytarabine
    29
    PI3Kγ inhibitor, PI3Kδ inhibitor
    duvelisib
    30
    Topoisomerase II inhibitor, Alkylating agent
    cyclophosphamide + etoposide IV
    31
    SIK3 inhibitor, PI3K inhibitor, PI3Kγ inhibitor, PI3Kδ inhibitor
    RP6530
    32
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    33
    HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    chidamide
    34
    DNMT inhibitor, Chemotherapy
    CHOP + azacitidine oral
    35
    CD30 inhibitor, CD16A agonist
    AFM13
    36
    TNFα inhibitor, IL-12 inhibitor, CD30-targeted antibody-drug conjugate, IL-6 inhibitor, Microtubule inhibitor, CD20 inhibitor
    rituximab + lenalidomide + brentuximab vedotin
    37
    TNFα inhibitor, PD-L1 inhibitor, IL-12 inhibitor, IL-6 inhibitor
    durvalumab + lenalidomide
    38
    CD79b-targeted antibody-drug conjugate, Microtubule inhibitor
    ARC-02
    39
    CD38 inhibitor, CD3 agonist, CD28 agonist
    SAR442257
    40
    IKZF1 degrader, IKZF3 degrader
    CFT7455
    41
    CD22-targeted antibody-drug conjugate, Microtubule inhibitor
    TRPH-222
    42
    DNA replication inhibitor, CD70-targeted antibody-drug conjugate
    SGN-CD70A
    43
    Multi-tyrosine kinase inhibitor
    gilteritinib
    44
    P21-activated kinase inhibitor
    FRAX597 + PF-3758309
    45
    ALK inhibitor, PP2A inhibitor
    crizotinib + LB-100
    No biomarker
    ALK positive
    ALK fusion
    TNFRSF8 positive
    TNFRSF8 expression
    TNFRSF8 negative
    PD-1 overexpression
    CXCL12 overexpression
    CXCL12 expression
    RHOA mutation
    RHOA G17V
    PD-L1 underexpression
    KIR3DL2 Q386E
    PD-L1 overexpression
    KIR3DL2 C336R
    ICOS underexpression
    RPS6 underexpression
    IDH2 mutation
    CD70 expression
    IL2RA expression
    LMO2 overexpression
    IL10-L
    TNFA-L
    CCL20-L
    CD20 overexpression
    NPM1-ALK fusion
    TSC2 mutation
    VAV1 mutation
    CD70 overexpression
    IL10 elevation
    PAK1 overexpression
    DNMT3A mutation
    ALK negative + TP53 deletion
    TET2 mutation
    Chr del(17p)
    TP53 deletion
    TP53 mutation
    CD28 expression
    CD22 positive
    CD79B expression
    CD38 expression